Companion Diagnostics and Precision Immune Cell Analysis: From Pre-Treatment Assessment and Post-Treatment Monitoring to Cell Manufacturing and Drug Development

TL;DR
- A companion diagnostic (CDx) is a test that provides information essential for the safe and effective use of a specific drug or biological product; its uses can include identifying patients more likely to benefit and monitoring treatment response.
- Not every immune cell test, treatment follow-up or cell quality test is a CDx. Whether a test qualifies depends on its relationship to a specific therapy, its intended use, and the corresponding validation and regulatory requirements.
- Flow cytometry can characterize immune cell populations, phenotypes and functional markers, but a single marker or a single percentage cannot on its own determine disease status or treatment effect.
- Comparing a patient before and after treatment looks at how the body responds to therapy; comparing cells before and after culture looks at the manufacturing process and product characteristics. The two serve different purposes.
- Depending on project needs, Neogenesis Biotech can work with pharmaceutical companies, biotech companies and cell therapy laboratories on immune monitoring, longitudinal follow-up, cell manufacturing analysis and the evaluation of future CDx co-development.
Contents
- What is a companion diagnostic (CDx)?
- Flow cytometry makes immune cell changes observable and comparable
- Before treatment: establishing an immune baseline to support patient stratification and screening research
- During and after treatment: understanding immune changes through multi-timepoint monitoring
- Cell manufacturing: building quality analysis data from pre-culture to post-culture
- Pharmaceutical companies and cell therapy laboratories: from testing partnerships to study design
- Neogenesis Biotech's direction: connecting testing, manufacturing and clinical research
Understanding the state of cells and how they change is an essential foundation that connects precision testing, therapy research and product development.
Why might different patients respond differently to the same treatment? What changes occur in immune cells after drug or cell therapy? After cells are isolated, cultured and expanded, do they still retain the expected characteristics?
Answering these questions requires systematic cell analysis and the accumulation of data over time.
Neogenesis Biotech is built around precision immune cell analysis. We are developing research applications that span pre-treatment assessment, monitoring during and after treatment, and cell manufacturing analysis, and we are exploring partnerships with pharmaceutical companies, biotech companies, medical institutions and cell therapy laboratories to lay the groundwork for biomarker research and future companion diagnostic development.
What is a companion diagnostic (CDx)?
A companion diagnostic (CDx) is a test that provides information essential for the safe and effective use of a specific drug or biological product.
According to the U.S. Food and Drug Administration (FDA), the uses of a companion diagnostic can include identifying patients who are most likely to benefit, identifying patients at increased risk of serious adverse reactions, and monitoring treatment response to support necessary adjustments to treatment. Its application is therefore not limited to the period before treatment begins and may extend into the course of treatment. (fda.gov)
However, not every immune cell test, treatment follow-up or cell quality test is a CDx. Whether a test constitutes a companion diagnostic depends on its relationship to a specific therapy, its intended use, and the corresponding validation and regulatory requirements.
Precision immune cell analysis can support related research, but developing a research assay into a CDx still requires reliable methods and clinical evidence.
Flow cytometry makes immune cell changes observable and comparable
Flow cytometry uses combinations of different markers to analyze the characteristics of individual cells and identify immune cell populations and their phenotypes. With an appropriate experimental design, it can also be used to study cell proliferation, activation or specific functional responses.
Depending on the research purpose and assay method, the parameters that can be observed include:
- The proportions of different immune cell populations, and cell counts obtained with appropriate methods.
- The phenotypic characteristics of T cells and their subsets.
- Immunoregulatory populations such as regulatory T cells (Tregs).
- Expression of markers associated with activation, differentiation or exhaustion.
- Cell viability, proliferation and validated functional markers.
A single marker usually cannot fully represent cell function, and disease status or treatment effect cannot be determined from whether one percentage is high or low. Results need to be interpreted together with multiple markers, sampling conditions and clinical data to be meaningful.
Before treatment: establishing an immune baseline to support patient stratification and screening research
Cell analysis before treatment can establish a patient's immune baseline as the starting point for later comparisons.
Research teams can then explore questions such as: Which immune cell characteristics are associated with disease status? Which markers may be associated with treatment response or risk? Do participants with different immune profiles show different study outcomes?
These data can support participant stratification, biomarker discovery and the development of screening strategies in clinical trials. If future evidence shows that a test is necessary for the safe and effective use of a specific therapy, its potential for CDx development can then be evaluated.
For both tumor cell therapy and autoimmune disease research, assay design should match the disease mechanism and treatment goals of each, with appropriate analysis parameters and interpretation methods.
During and after treatment: understanding immune changes through multi-timepoint monitoring
A single test reflects the state at one point in time; monitoring at multiple timepoints helps reveal the direction and duration of change.
For example, depending on the drug's mechanism of action, route of administration and disease characteristics, a study protocol might schedule sampling before treatment, early in treatment, and at three months, six months or one year. The actual schedule should be decided by the study protocol and the medical team.
With consistent sampling, testing and analysis methods, research can examine:
- Whether immune cell composition changes before and after treatment.
- Whether changes in specific cell populations or phenotypes persist.
- Whether cellular changes are associated with clinical indicators, treatment response or adverse events.
- Whether groups with different treatment responses show immune characteristics that can be further validated.
This type of research can be applied to cell therapy, immunotherapy, and the development of targeted or other drugs where there is a relevant research need. Whether it is applicable, and which parameters should be tested, must still be evaluated for each product and research question.
Immune cell changes are research clues; on their own, they cannot serve as proof that a treatment works, that a disease has improved or that an organ has been repaired. Results should be analyzed together with disease-specific indicators and clinical outcomes.
Cell manufacturing: building quality analysis data from pre-culture to post-culture
Beyond observing immune changes in patients, cell analysis can also be used in manufacturing research for cell products.
Across the stages of cell isolation, activation, culture, expansion and storage, research teams can compare cell characteristics at different timepoints or under different process conditions to understand whether the process is producing the expected results.
Depending on the cell product and method design, the attributes that can be evaluated include cell identity, purity, viability, the proportion of the target population, phenotypic and functional markers, and consistency between batches.
There are two different kinds of "before and after" comparison here:
Comparing a patient before and after treatment looks at how the body responds to therapy; comparing cells before and after culture looks at the manufacturing process and product characteristics.
Process analysis and quality control (QC) can support the generation of Chemistry, Manufacturing and Controls (CMC) data, but a test does not automatically become a CDx simply because it uses the same flow cytometry technology. If a test will be used for potency assessment or product release, fit-for-purpose method validation and acceptance criteria must also be established.
Pharmaceutical companies and cell therapy laboratories: from testing partnerships to study design
The value of precision immune cell analysis also lies in helping partners turn research questions into executable testing and data analysis plans.
Neogenesis Biotech looks forward to working with pharmaceutical companies, biotech companies and cell therapy laboratories to jointly evaluate the following areas of collaboration, based on the needs of each project:
1. Immune monitoring and biomarker discovery
Plan test parameters according to the product's mechanism and disease characteristics, study cellular changes before and after treatment, and analyze their association with clinical outcomes.
2. Longitudinal monitoring design
Jointly plan sampling timepoints, sample handling and analysis workflows to build comparable follow-up data.
3. Cell manufacturing and quality analysis
Compare cell characteristics before and after culture, under different culture conditions, or before and after process changes, to support process optimization and batch consistency studies.
4. Testing strategy and data interpretation
From the research question and panel design to the presentation of results, discuss suitable analytical methods and their limitations, and help teams set the direction for subsequent validation.
5. Evaluation of future CDx co-development
If research results support a necessary link between a test and a specific treatment decision, the requirements for method validation, clinical validation and regulatory development can be further evaluated.
The actual scope of each collaboration should be confirmed according to project needs, existing technical capabilities, the degree of method validation and applicable regulations.
Neogenesis Biotech's direction: connecting testing, manufacturing and clinical research
Neogenesis Biotech focuses on research needs in tumor immunology and autoimmune disease, including cell research related to tumor-infiltrating lymphocytes (TILs), as well as immunology research related to type 1 diabetes (T1D), latent autoimmune diabetes in adults (LADA) and regulatory T cells (Tregs).
Across different studies, patient immune monitoring, cell manufacturing analysis and CDx development each serve a different purpose. Our approach is to build suitable testing methods, quality processes and data evidence step by step, according to the research stage of each project.
From the pre-treatment baseline, to cell characteristics during manufacturing, to post-treatment follow-up, linking every test to a clearly defined question is what turns cell data into a valuable basis for research and development.
Discuss your immune cell analysis needs with Neogenesis Biotech
If you are from a pharmaceutical company, biotech company, medical institution or cell therapy laboratory, you are welcome to contact Neogenesis Biotech to discuss potential collaboration on immune monitoring, biomarker discovery, cell manufacturing analysis and future companion diagnostic development.
This article introduces research and technical applications. Actual test parameters, scope of services and clinical uses are confirmed according to each project, validation results and applicable regulations.
FAQ
How is a companion diagnostic different from general immune cell testing?
General immune cell testing can be used to understand cell composition and phenotype, or to study related functions. A CDx has a more specific purpose: to provide information essential for the safe and effective use of a specific therapy. Not every immune test is therefore a CDx.
Can companion diagnostics only be used before treatment?
Not necessarily. Depending on its intended use, a CDx may also be used to monitor response during treatment and support necessary treatment adjustments. Whether general post-treatment follow-up counts as a CDx still depends on whether it meets the relevant definitions and requirements.
Can flow cytometry tell whether a drug works?
Flow cytometry can provide data on cellular changes, but it cannot prove on its own that a drug is effective. Results must be combined with clinical endpoints, disease indicators and an appropriate study design to assess their significance.
Why is follow-up needed at three months, six months or one year after treatment begins?
Different timepoints help show when changes occur, how long they last and whether they recover. Not every study needs the same schedule; it should be planned according to the disease, the treatment and the research purpose.
Does QC during cell culture count as a companion diagnostic?
It usually serves a different purpose. Process QC mainly evaluates the quality of the cell product and the manufacturing process, whereas a CDx relates to the safe and effective use of a specific therapy in patients. Even when the same technology is used, methods and standards need to be established separately.
Can immune cell monitoring be used with targeted drugs or other drugs?
If the drug's mechanism and the research question are suitable, adding immune cell monitoring can be evaluated. Not every drug needs the same panel, and not every type of monitoring can be developed into a CDx; it should be designed project by project.
How can pharmaceutical companies or cell therapy laboratories work with Neogenesis Biotech?
Collaboration can start from a specific research question, such as participant stratification, immune changes before and after treatment, comparison of culture conditions or batch consistency, followed by a joint evaluation of samples, sampling timepoints, testing methods and data analysis needs.
Are Neogenesis Biotech's current related tests all approved CDx?
The immune cell analysis, research collaboration and future development directions described in this article do not mean that the related tests have received CDx approval. The intended use, degree of validation and regulatory status of each test should be based on the formal description of that service or project.
Can test results be used directly to decide on starting or stopping a drug, or on cell reinfusion?
Results from research assays should not be used on their own to decide on starting or stopping a drug, dosing or cell reinfusion. Such medical decisions should be made by a physician based on the approved use, clinical data and any applicable trial protocol.
Ready to start your precision medicine journey?
Contact our experts to learn about cellular intelligence and health management.
More in Clinical Research and Trial Progress
Keep reading on related topics
